Complicated Clinical Infections: Clinical Impact of New Data From ECCMID 2023

In this episode, David van Duin, MD, PhD, FIDSA, FAST, discusses new data on complicated clinical infections presented at ECCMID 2023, including:

• Gram-negative resistance
  • Pharmacokinetic and clinical outcomes in patients receiving meropenem/vaborbactam for KPC-producing carbapenem-resistant Enterobacterales infections
  • Comparative study of cefiderocol- vs colistin-containing regimens for CRAB VAP with concomitant bacteremia
  • Real-world use of imipenem/cilastatin/relebactam for the treatment of infections caused by multidrug-resistant organisms
• Antimicrobial stewardship
  • Safety and efficacy of antibiotic de-escalation from an antipseudomonal β-lactam in patients with Enterobacterales BSIs in SIMPLIFY
  • The SOAB study comparing clinical outcomes of switching to oral antibiotics after IV lead-in therapy vs continuing IV therapy in patients with Enterobacterales BSIs
  • Data from REGARD-VAP on outcomes of shortened antibiotic treatment for VAP guided by clinical criteria
• Investigational agents
  • Open-label study following ATTACK of patients with colistin-resistant CRAB infections receiving sulbactam/durlobactam
  • Summary of findings from EAGLE-2 and EAGLE-3 of gepotidacin for uncomplicated UTI treatment
  • Post hoc DOOR analysis of SURE-2 of sulopenem for the treatment of complicated UTIs

Faculty:
David van Duin, MD, PhD, FIDSA, FAST
Professor of Medicine
Director, Immunocompromised Host Infecious Diseases Program
Division of Infectious Diseases
University of North Carolina
Chapel Hill, North Carolina

Content based on an online CME/CE program supported by an independent educational grant from Shionogi Inc.

Link to full program: https://bit.ly/3niXGJ6

Link to downloadable slides: https://bit.ly/3Hx0ppn

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.